Aptevo Therapeutics Inc APVO The shares rise on Wednesday. According to data from Benzinga Pro, the share is higher with a strong volume of 81.8 million compared to the average volume of 275.3k. What happened: Aptevo revealed new clinical data from the current phase 1b/2 Rainier study for evaluation of mipletamig, the first-in-class CD123 x […]
